Creative Biolabs Expands Metabolic Disease Research Tools

New antibody portfolios target key regulators of insulin, lipid, and incretin signaling

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Creative Biolabs has announced the expansion of its extensively validated antibody catalog targeting critical nodes in metabolic regulation. The new portfolios focus on the glucagon-like peptide-1 receptor (GLP-1R), acetyl-CoA carboxylase (ACACA), and insulin receptor substrate 2 (IRS2) - key regulators of insulin, lipid, and incretin signaling. These high-fidelity research tools are designed to streamline the transition from basic research to preclinical drug discovery for metabolic disorders and weight management therapeutics.

Why it matters

Understanding the complex interplay between systemic hormones and cellular energy sensors is crucial for advancing metabolic disease research and developing more effective treatments. Creative Biolabs' new antibody portfolios provide researchers with the specificity and versatility required to accurately map these intricate pathways, addressing industry-wide challenges around target validation and cross-reactivity.

The details

The new antibody portfolios from Creative Biolabs target three critical nodes in metabolic regulation: GLP-1R, the cornerstone of incretin-based therapies for insulin secretion and appetite regulation; ACACA, a key regulator of intracellular lipid synthesis; and IRS2, vital for maintaining hepatic insulin sensitivity and beta-cell survival. These reagents are engineered to eliminate cross-reactivity through rigorous knockout validation and advanced epitope mapping, ensuring researchers can evaluate precise metabolic pathways. The antibodies are also optimized for diverse analytical applications, including flow cytometry, multiplex immunohistochemistry, and Western blotting, allowing for deep phenotyping of metabolic tissues.

  • Creative Biolabs announced the expansion of its antibody catalog on March 11, 2026.

The players

Creative Biolabs

A leading global provider of highly specific antibodies, recombinant proteins, and custom immunological services, committed to accelerating scientific discovery in areas like oncology, immunology, and metabolic disease research.

Bella Smith

Head of Scientific Outreach at Creative Biolabs, who stated that the company's new antibody portfolios are engineered to eliminate cross-reactivity and provide researchers with the high-quality, reproducible data required to advance the next generation of metabolic treatments.

Got photos? Submit your photos here. ›

What they’re saying

“The paradigm of metabolic therapeutics is shifting from single-target interventions to comprehensive, multi-pathway modulation.”

— Bella Smith, Head of Scientific Outreach (Creative Biolabs)

“Ensuring absolute target specificity when investigating the crosstalk between GLP-1R agonism and downstream effectors like ACACA and IRS2 is paramount. Our rigorously validated antibody portfolios are engineered to eliminate cross-reactivity, providing researchers with the high-quality, reproducible data required to advance the next generation of metabolic treatments.”

— Bella Smith, Head of Scientific Outreach (Creative Biolabs)

The takeaway

Creative Biolabs' new antibody portfolios targeting key metabolic regulators like GLP-1R, ACACA, and IRS2 are designed to help researchers overcome longstanding challenges in the field of metabolic disease research, enabling more precise investigations of complex signaling pathways and accelerating the development of innovative treatments for conditions like obesity and type 2 diabetes.